Danaher's AI-driven life-sciences expectations look excessive against its results. After a 44% rise since May on hopes AI would lift life sciences to unprecedented levels, it missed Q3 revenue and guided Q4 growth to just 4-5%. x.com 

AI-enabled drug discovery is the next re-rate, because if AI raises lab hit rates, the cost of failure falls across the sector and beaten-down platforms re-rate first. Recursion is the cleanest expression, an AI-first platform built to industrialize discovery. AbCellera and Tempus apply AI to antibody discovery and the diagnostics data layer, with real revenue under the story. The trap is paying a winner's multiple before the trial proves the winner. x.com 

Schrodinger deserves at least a 50% higher valuation than Salesforce, yet both trade near 3.9x EV/sales. The better test of AI is how much upside optionality an industry gains, not whether a company wins or loses: Salesforce's AI upside is capped because demand is saturated and it must fight to capture value across the stack. Biotech research is far more uncapped, since better modeling could turn a pipeline of 3 drug candidates into 30 with higher approval odds. x.com 

Pure-play AI drug discovery names, including Recursion, Schrödinger, Relay Therapeutics, Absci and Tempus AI, look well positioned as a basket. x.com 

Recursion Pharmaceuticals could see huge catalysts from positive phase I and II news due in the second half of this year. Its AI drug-discovery platform has five clinical trials in progress, and big pharma and biopharma are spending billions on AI-driven platforms. Market research firms project 38-45% annual growth for AI genomics through the early 2030s. The stock found support around $3 and has some momentum. x.com 

Bruker's 20% drop on an unremarkable quarter looks overdone, and about half that loss should recover quickly. Its technology is incredible even if management is less than stellar, and eventually the technology is all that will matter. The AI-driven biotech capital spending boom has yet to arrive after Trump-administration cuts, and the inflection should be huge; as AI showed, buyers fight for scarce equipment at multiples of prior prices, so any AI aspirant should want a piece of Bruker. x.com  … Show more

The biotech and genomics boom is best owned broadly, because single biotech stocks are binary bets on trial results no analyst can handicap. One failed readout can halve a stock, as Novo Nordisk's lost market value on disappointing data showed. Owning blue-chip biotech and high-beta genomics as diversified baskets captures the funding rebound, the AI drug-discovery tailwind and the re-rating after years of deep bear market and a decisive breakout, without the single-molecule lottery. x.com  x.com  … Show more